8-K: Incannex Reports Positive Phase 2 Results for OSA Drug IHL-42X

Incannex Healthcare Inc. announced positive topline results from its RePOSA Phase 2 clinical trial for IHL-42X, a novel oral drug candidate for obstructive sleep apnoea, demonstrating significant efficacy and an outstanding safety profile.

Summary

• Positive topline results were reported from the RePOSA Phase 2 clinical trial evaluating IHL-42X, a novel oral drug candidate for obstructive sleep apnoea (OSA).
• IHL-42X demonstrated statistically significant and clinically meaningful improvements across key clinical endpoints.
• Maximum reductions in Apnoea-Hypopnoea Index (AHI) were observed at up to 83% for the high-dose group and up to 79% for the low-dose group from baseline.
• A significant portion of patients achieved substantial AHI reductions: 33.3% in the low-dose group and 41.2% in the high-dose group achieved greater than 30% reduction, while 13.9% (low-dose) and 14.7% (high-dose) experienced reductions exceeding 50%.
• Statistically significant improvements were noted in Patient Global Impression of Change (PGI-C) for sleep-related impairment and fatigue in the low-dose group.
• Both lowand high-dose groups showed statistically significant improvements in Oxygen Desaturation Index (ODI).
• Clinically significant improvements were reported in patient-reported outcome measures, including FOSQ-10, PROMIS Sleep-Related Impairment 8a, PROMIS Fatigue 7a, and Epworth Sleepiness Scale (ESS).
• Objective sleep parameters measured by Polysomnography (PSG) improved, with Wake After Sleep Onset (WASO) reduced by 29.8% and AHI During Supine Sleep decreased by 30.3% in the high-dose arm.
• IHL-42X was well tolerated across both dose cohorts, with no serious adverse events reported and treatment-emergent adverse effects (TEAEs) being infrequent and mostly mild or moderate.
• The RePOSA Phase 2 trial was a randomized, double-blind, placebo-controlled study involving 121 adult participants with confirmed moderate to severe OSA, treated for a 28-day period.

Sentiment

Score: 9

Explanation: The filing reports overwhelmingly positive Phase 2 clinical trial results for a drug targeting a large unmet medical need, with strong efficacy and an excellent safety profile that exceeded expectations. This is a significant de-risking event for the company's lead candidate.

Positives

• Statistically and clinically significant improvements were achieved across multiple key clinical endpoints for IHL-42X.
• IHL-42X reduced Apnoea-Hypopnoea Index (AHI) by up to 83% from baseline in the high-dose group and up to 79% in the low-dose group.
• A substantial subset of patients showed strong therapeutic response, with 33.3% (low-dose) and 41.2% (high-dose) achieving greater than 30% AHI reduction, and 13.9% (low-dose) and 14.7% (high-dose) achieving greater than 50% AHI reduction.
• Statistically significant improvements were observed in Patient Global Impression of Change (PGI-C) for sleep-related impairment and fatigue.
• Oxygen Desaturation Index (ODI) showed statistically significant improvements in both lowand high-dose groups.
• Clinically significant improvements were noted in patient-reported outcome measures, including FOSQ-10, PROMIS-SRI 8a, PROMIS Fatigue 7a, and ESS.
• Objective sleep parameters improved, with Wake After Sleep Onset (WASO) reduced by 29.8% and AHI During Supine Sleep decreased by 30.3% in the high-dose arm.
• IHL-42X demonstrated an outstanding safety profile, being well tolerated with no serious adverse events and infrequent, mild or moderate treatment-emergent adverse effects.
• The compelling efficacy and exceptional safety profile position IHL-42X as a potential transformative therapy and a leading drug candidate in the global race to bring an oral pharmaceutical treatment for OSA to market.

Risks

• The continued availability of financing is a risk.
• Ability to raise capital to fund continuing operations, complete capital raising transactions, and maintain or potentially further improve the capital structure is a risk.
• Ability to maintain the listing of common stock on the Nasdaq Stock Market is a risk.
• The impact of any infringement actions or other litigation brought against the company is a risk.
• Success of development efforts, including the ability to progress drug candidates through clinical trials on expected timelines (e.g., successfully completing the Phase 3 trial for IHL-42X) and obtaining necessary regulatory approvals for commercialization, is a risk.
• The effects of competition from other existing or future providers and products are a risk.
• The market for drug candidates may not grow at anticipated rates or at all, or market estimates may ultimately be incorrect.
• Inability to successfully execute upon any commercial discussions is a risk.
• Ability to comply with various evolving and complex laws and regulations applicable to the business and industry is a risk.
• Ability to protect proprietary technology and intellectual property is a risk.

Future Outlook

Incannex is now focused on advancing IHL-42X toward commercial readiness. Preparations are in progress for the company's End-of-Phase 2 meeting with the FDA, which is expected to provide critical guidance for optimizing the Phase 3 trial design and regulatory strategy. In parallel, the company will continue to evaluate all clinical data and complete the full Clinical Study Report in the coming months. Incannex will also continue to facilitate commercial discussions.

Management Comments

• "We are extremely pleased with the RePOSA trial results. The combination of statistically significant improvements across multiple endpoints and an outstanding safety profile positions IHL-42X as one of the most compelling drug candidates in the global race to bring a pharmaceutical treatment for OSA to market." Joel Latham, CEO and President of Incannex.
• "The depth of response seen in a defined subset of patients further reinforces our belief in its clinical and commercial potential. These results are a clear signal of the strength of our development strategy and a critical step forward in building long-term shareholder value." Joel Latham, CEO and President of Incannex.
• "These findings highlight the statistically significant treatment effects observed across multiple measures of disease severity and patient experience. Combined with an excellent safety and tolerability profile, the results provide strong validation of IHL-42Xs potential as an innovative and impactful therapy for obstructive sleep apnea." Dr. Mark Bleackley, Chief Scientific Officer of Incannex.

Industry Context

Obstructive Sleep Apnoea (OSA) affects over 900 million people globally, representing a significant unmet medical need as there are currently no approved oral pharmaceutical treatments available. IHL-42X's robust efficacy and exceptional safety profile position it as a potential transformative therapy, aiming to address this large global market.

Comparison to Industry Standards

• There are currently no approved oral pharmaceutical treatments for Obstructive Sleep Apnoea (OSA) globally, positioning IHL-42X to potentially fill a significant unmet medical need.
• The results demonstrate "statistically significant and clinically meaningful improvements across key endpoints," reinforcing IHL-42X's potential as a "best-in-class therapy" for OSA patients.
• The "outstanding safety profile that exceeded expectations" is a strong differentiator in the development of new drug candidates.

Stakeholder Impact

• Shareholders: The positive trial results are expected to build long-term shareholder value and represent a critical step forward in the company's development strategy.
• Patients (OSA): IHL-42X offers the potential for a transformative, effective, and safe oral pharmaceutical treatment for obstructive sleep apnoea, a condition affecting over 900 million people globally with no current approved oral options.

Next Steps

• Advance IHL-42X toward commercial readiness.
• Prepare for the End-of-Phase 2 meeting with the FDA to discuss the most efficient path to registration and optimize Phase 3 trial design and regulatory strategy.
• Evaluate all clinical data and complete the full Clinical Study Report in the coming months.
• Continue to facilitate commercial discussions.

Key Dates

Recommendation

The positive topline Phase 2 results for IHL-42X are a major de-risking event for Incannex's lead drug candidate, addressing a significant unmet medical need in a large global market with no approved oral treatments. The demonstrated efficacy (up to 83% AHI reduction) combined with an outstanding safety profile positions IHL-42X as a potential best-in-class therapy. This strong clinical validation significantly enhances the drug's commercial potential and the company's long-term shareholder value, making it a highly attractive investment.

Keywords

Obstructive Sleep Apnoea, OSA, IHL-42X, Phase 2, Clinical Trial, Topline Results, Drug Candidate, Pharmaceutical, Sleep Apnea Treatment, Nasdaq, Incannex Healthcare, Dronabinol, Acetazolamide, Polysomnography, AHI, ODI, FDA